{"name":"EMD Serono Research & Development Institute, Inc.","slug":"emd-serono-research-development-institute-inc","ticker":"","exchange":"","domain":"emdseronoresearchdevelopmentinstitute.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"MSC2364447C","genericName":"MSC2364447C","slug":"msc2364447c","indication":"Other","status":"phase_1"},{"name":"M3814 200 mg","genericName":"M3814 200 mg","slug":"m3814-200-mg","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Avelumab Weekly","genericName":"Avelumab Weekly","slug":"avelumab-weekly","indication":"Metastatic Merkel cell carcinoma","status":"phase_3"},{"name":"Fluorouracil (5-FU)","genericName":"Fluorouracil (5-FU)","slug":"fluorouracil-5-fu","indication":"Colorectal cancer","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Rebif® new formulation (RNF)","genericName":"Rebif® new formulation (RNF)","slug":"rebif-new-formulation-rnf","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Tecfidera","genericName":"Tecfidera","slug":"tecfidera","indication":"Plaque psoriasis","status":"marketed"}]}],"pipeline":[{"name":"MSC2364447C","genericName":"MSC2364447C","slug":"msc2364447c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Avelumab Weekly","genericName":"Avelumab Weekly","slug":"avelumab-weekly","phase":"phase_3","mechanism":"Avelumab is a human monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors to reinvigorate anti-tumor immune responses.","indications":["Metastatic Merkel cell carcinoma","Urothelial carcinoma (bladder cancer)","Non-small cell lung cancer"],"catalyst":""},{"name":"Fluorouracil (5-FU)","genericName":"Fluorouracil (5-FU)","slug":"fluorouracil-5-fu","phase":"phase_3","mechanism":"Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.","indications":["Colorectal cancer","Breast cancer","Gastric cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"M3814 200 mg","genericName":"M3814 200 mg","slug":"m3814-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rebif® new formulation (RNF)","genericName":"Rebif® new formulation (RNF)","slug":"rebif-new-formulation-rnf","phase":"phase_3","mechanism":"Rebif new formulation (RNF) is an interferon beta-1a used to treat multiple sclerosis.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"Tecfidera","genericName":"Tecfidera","slug":"tecfidera","phase":"marketed","mechanism":"Hydroxycarboxylic acid receptor 2, Kelch-like ECH-associated protein 1","indications":["Plaque psoriasis","Relapsing remitting multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":2,"phase_3":3,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}